Dr. Li Wen | Nephrology | Best Researcher Award

The Affiliated Hospital of Southwest Medical University | China

Dr. Li Wen is a dedicated Associate Professor at The Affiliated Hospital of Southwest Medical University, specializing in nephrology. With a strong background in both clinical practice and academic research, she has made substantial contributions to understanding kidney diseases, particularly acute kidney injury and chronic renal failure. Her work stands at the intersection of patient care and translational research, bridging laboratory discoveries with therapeutic advancements.

Professional profile👤

Scopus

Strengths for the Awards✨

Dr. Li Wen stands out as a distinguished researcher and clinician in the field of nephrology, with a commendable balance between academic scholarship and clinical expertise. As an Associate Professor at The Affiliated Hospital of Southwest Medical University, her contributions to the understanding of acute kidney injury (AKI), renal fibrosis, and epigenetic regulation in kidney disease are noteworthy.

Her publication record includes five SCI-indexed articles, with research featured in prestigious journals like Cell Death & Disease and Acta Pharmacologica Sinica. Her studies, especially on the EZH2 pathway, have important translational implications in kidney disease treatment, advancing both scientific knowledge and potential therapeutic strategies. Furthermore, Dr. Wen has received research funding across provincial, municipal, and university levels, reflecting strong institutional support and recognition. Her collaborative ties with West China Hospital of Sichuan University also indicate a broader academic network and interdisciplinary engagement.

🎓 Education

Li Wen has pursued advanced studies in medicine and nephrology, culminating in her academic and clinical tenure at The Affiliated Hospital of Southwest Medical University. Her rigorous academic path has equipped her with the expertise required for specialized care in nephrology and cutting-edge research on renal pathophysiology.

💼 Experience

Currently serving as an Associate Professor, Li Wen plays a pivotal role in both clinical services and scientific research. Her experience spans across managing patients with hemodialysis needs and nephrotic syndromes, as well as mentoring young researchers. She collaborates closely with prestigious institutions like West China Hospital of Sichuan University to advance multidisciplinary nephrology research.

🔬 Research Interests On Nephrology

Dr. Wen’s research is centered on epigenetic and molecular mechanisms underlying kidney injury and fibrosis, particularly focusing on EZH2, NLRP3 inflammasome pathways, and NF-κB signaling. She explores how these pathways contribute to renal damage and healing, aiming to translate molecular insights into potential therapeutic interventions for acute and chronic kidney conditions.

🏆 Awards

Li Wen has received individual funding at the provincial, municipal, and university levels, recognizing her outstanding contributions to nephrology research. Her work is frequently cited in high-impact journals, establishing her reputation as a thought leader in the field of renal medicine.

📚 Publications

Dr. Li Wen has published 5 SCI-indexed research papers, each contributing meaningfully to the field of nephrology:

1. Tubular aryl hydratocarbon receptor upregulates EZH2 to promote cellular senescence in cisplatin-induced acute kidney injury
   Cell Death & Disease, 2023; 14(1): 18 – Cited by multiple recent nephrology reviews.

2. Selective EZH2 inhibitor zld1039 alleviates inflammation in cisplatin-induced acute kidney injury partially by enhancing RKIP and suppressing NF-κB p65 pathway
   Acta Pharmacologica Sinica, 2021; 43(8): 2067–2080 – Widely referenced in inflammation and pharmacology research.

3. The EZH2 selective inhibitor ZLD1039 attenuates UUO-induced renal fibrosis by suppressing YAP activation
   Molecular Biomedicine, 2025; 6(1): 36 – Recent article gaining traction in renal fibrosis literature.

4. The Emerging Role of Epigenetic Methylation in Kidney Disease
   Current Medicinal Chemistry, 2021; 29(21): 3732–3747 – Cited for its comprehensive review of epigenetic regulators in nephrology.

5. The roles of NLRP3 inflammasome-mediated signaling pathways in hyperuricemic nephropathy
   Molecular and Cellular Biochemistry, 2021; 476(3): 1377–1386 – Referenced in studies on metabolic kidney diseases.

🧾 Conclusion

🔍 With a passion for renal research and a consistent track record of clinical excellence, Dr. Li Wen is a highly deserving candidate for the Best Researcher Award. Her investigations into EZH2’s role in renal pathologies not only expand scientific understanding but also have real-world applications in patient care. Through her collaborative efforts, impactful publications, and ongoing commitment to innovation, she exemplifies the spirit of academic and clinical leadership in nephrology.